Avantel approves merger of wholly owned subsidiary Imeds Global

The merger in numbers

The rationale the filing gives

The filing says the merger is intended to rationalise the group structure, simplify governance and reporting, consolidate operations and resources, and eliminate duplication of administrative and compliance functions. The stated aims also include improved operational efficiency and better management and oversight.

The merger falls within related party transactions and is covered by an exemption under the listing rules, the filing says. No share exchange ratio applies, and Imeds Global is a wholly owned subsidiary.

What the two companies do

Imeds Global makes medical electronic devices and healthcare solutions, covering respiratory care, patient monitoring, surgical instruments, endoscopy and homecare. Avantel designs, manufactures and commissions defence electronics, satellite communication systems and telecom systems.

A new Director (Technical) on the board

The Board appointed Nimmagadda Sreenivasa Rao as an Additional Director, designated Director (Technical), for three consecutive years from 26 Oct 2026 to 25 Oct 2029, subject to approval by members through Postal Ballot. He joined Avantel in 1997 as an RF Design Engineer and is now Vice President - Technical, heading the R&D department.

What the merger and the appointment mean for Avantel's shareholders

No Avantel shares are to be allotted under the scheme, and the shareholding pattern will not change, the filing says. The filing does not give the effective date, the NCLT timeline or the effect of the merger on Avantel's results.

The next steps are NCLT sanction and member approval of the director appointment through Postal Ballot. No dates are given for either.

Reference: Original filing (PDF)